DeepSight Technology

About DeepSight Technology

DeepSight Technology, Inc., founded in 2019, is a medical technology firm focused on advancing diagnostic ultrasound imaging. The company was established by co-founders Nader Sadrzadeh (CEO), Lan Yang (CTO), and Anand Chandrasekher with a vision to overcome the limitations of conventional ultrasound. Sadrzadeh has a 25-year background in commercializing technology, including serving as CEO of Kionix, a MEMS sensor company, and as a Senior VP at ROHM Semiconductor. This experience in sensor technology and product development led to the application of co-founder Dr. Lan Yang's sensor technology to medical ultrasound.

The company is developing a new class of ultrasound technology that combines proprietary hardware, software, and AI algorithms. At its core, the technology uses Whispering Gallery Mode (WGM) micro-resonators instead of traditional piezoelectric transducers to detect resonant frequency shifts with light. This approach is designed to provide significantly higher sensitivity and clarity, more than doubling the effective imaging range compared to conventional systems. By improving image quality and depth penetration, DeepSight aims to expand the applications of ultrasound, potentially reducing the need for more costly and less accessible modalities like CT or MRI. The firm's intellectual property portfolio includes over 100 granted and pending patents.

DeepSight's business model encompasses diagnostic imaging solutions, guidance for therapeutic tools, AI-powered analytics, and technology licensing partnerships with other companies. The company's target clients are clinicians and healthcare providers. Its product pipeline includes the EchoLux™ Ultrasound System, a premium cart-based platform, and the NeedleVue™ solution. NeedleVue™ integrates tiny, non-electrical sensors into the tips of needles and catheters to provide enhanced visibility for ultrasound-guided procedures, such as biopsies. The technology is designed to be self-calibrating and provides comprehensive visibility regardless of the instrument's angle. In October 2021, the company announced a $25 million Series A funding round led by Deerfield Management Company, with participation from Wing, Alter Venture Partners, and Time BioVentures, to advance product development and scale its operations. DeepSight's products are currently for investigational use and have not yet received FDA approval for sale.